Business Context and Reporting Period
Company: MUSTANG BIO, INC. (MBIO)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2024
Business Overview: Mustang Bio is a clinical-stage biopharmaceutical company focused on cell and gene therapies for hematologic cancers and solid tumors. The company is a majority-controlled subsidiary of Fortress Biotech, Inc. It has no approved products and has not generated any product revenue to date.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(8,199) | $(16,235) | $(13,390) | $(32,928) |
| Operating Expenses | $8,540 | $13,891 | $13,771 | $30,212 |
| Cash & Equivalents (End of Period) | $4,268 | $15,385 | $4,268 | $15,385 |
| Total Assets | $8,519 | $17,742 | $8,519 | $17,742 |
| Stockholders' Equity | $(8,330) | $13,713 | $(8,330) | $13,713 |
Note: The company reported negative stockholders' equity of $8.3 million as of June 30, 2024, compared to positive equity of $123,000 at year-end 2023.
Material Changes vs. Prior Period
- Significant Cost Reductions: Total operating expenses decreased by 39% in Q2 2024 compared to Q2 2023, driven by an 81% workforce reduction in April 2024 and the termination of several license agreements (St. Jude, Leiden University, Mayo Clinic).
- Asset Impairment: The company recorded a non-cash asset impairment charge of $2.6 million in Q2 2024 related to leasehold improvements and right-of-use assets, following the decision to abandon the sale of its manufacturing facility.
- Facility Transaction Reversal: A previously announced sale of the Worcester manufacturing facility to uBriGene was abandoned due to CFIUS national security concerns. In June 2024, the company repurchased the assets for approximately $1.4 million (plus forgiveness of receivables/payables), resulting in a net purchase consideration of ~$4.7 million.
- Debt Elimination: Interest expense dropped significantly as the company repaid its Term Loan in April 2023; Q2 2024 interest expense was negligible ($2,000) compared to $2.9 million in Q2 2023.
- Financing Activity: The company raised approximately $5.3 million in net proceeds from two equity offerings in May and June 2024 (May 2024 Public Offering and June 2024 Registered Direct Offering).
Guidance, Outlook, and Risks
- Going Concern: Management has concluded there is substantial doubt regarding the company's ability to continue as a going concern for 12 months from the filing date. The company expects to incur continued losses and requires additional financing to fund operations into the fourth quarter of 2024.
- Strategic Pivot: The company has pivoted to focus primarily on its lead product candidate, MB-106 (CD20-targeted CAR T), and has terminated development of MB-102, MB-103, MB-104, MB-105, MB-107, MB-110, and the Mayo Clinic in vivo CAR-T program.
- Regulatory Status: MB-106 received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. However, due to resource constraints, the company does not expect to initiate its pivotal Phase 2 trial for Waldenström's macroglobulinemia in 2024.
- Nasdaq Compliance: The company received deficiency notices from Nasdaq regarding minimum stockholders' equity and minimum bid price requirements. It has been granted extensions to regain compliance by September 9, 2024 (equity) and November 12, 2024 (bid price).
- Capital Constraints: The company is subject to "baby shelf rules," limiting the amount of securities it can sell under its Form S-3 registration statement to one-third of its public float until the float exceeds $75 million.
Investor Verification Checklist
- Liquidity Runway: Verify if the $4.3 million cash balance plus recent financing proceeds is sufficient to fund operations through Q4 2024 as projected, given the high burn rate.
- Nasdaq Delisting Risk: Monitor the company's progress in regaining compliance with Nasdaq listing standards (equity and bid price) by the September and November 2024 deadlines.
- MB-106 Trial Timeline: Confirm the specific timeline for initiating the pivotal Phase 2 trial for MB-106, as the company currently does not expect to start in 2024.
- Future Financing Terms: Assess the potential dilution impact of future equity raises, noting the existing 2.5% annual dividend to Fortress Biotech and the "baby shelf" limitations.
- Asset Repurchase Obligations: Review the terms of the deferred payment ($1.3 million) for the repurchased assets from uBriGene and the conditions for extension.